Cargando…

Combined Treatment with Ultrasound and Immune Checkpoint Inhibitors for Prostate Cancer

Background: Ultrasound (US) is mostly used for diagnostic purpose but could be used for cancer treatments with a US intensity or frequency fitted to such a purpose. Prostate cancer (PC) has the highest prevalence in the urological field, but indications for immune checkpoint inhibitors (ICIs) for PC...

Descripción completa

Detalles Bibliográficos
Autores principales: Hayashi, Fuuka, Shigemura, Katsumi, Maeda, Koki, Hiraoka, Aya, Maeshige, Noriaki, Ooya, Tooru, Sung, Shian-Ying, Yang, Yong-Ming, Fujisawa, Masato
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9104877/
https://www.ncbi.nlm.nih.gov/pubmed/35566574
http://dx.doi.org/10.3390/jcm11092448
_version_ 1784707902042275840
author Hayashi, Fuuka
Shigemura, Katsumi
Maeda, Koki
Hiraoka, Aya
Maeshige, Noriaki
Ooya, Tooru
Sung, Shian-Ying
Yang, Yong-Ming
Fujisawa, Masato
author_facet Hayashi, Fuuka
Shigemura, Katsumi
Maeda, Koki
Hiraoka, Aya
Maeshige, Noriaki
Ooya, Tooru
Sung, Shian-Ying
Yang, Yong-Ming
Fujisawa, Masato
author_sort Hayashi, Fuuka
collection PubMed
description Background: Ultrasound (US) is mostly used for diagnostic purpose but could be used for cancer treatments with a US intensity or frequency fitted to such a purpose. Prostate cancer (PC) has the highest prevalence in the urological field, but indications for immune checkpoint inhibitors (ICIs) for PC are limited to very few cases. In this study, we compared the antitumor effect of US irradiation alone with the combined use of US and ICIs in vitro and in vivo. Methods: PC cell line TRAMP-C2 cells were used in our experiments. TRAMP-C2 cells were irradiated with US with pulse repeated frequencies (PRF) of 1, 10, and 100 Hz. Cell proliferation was evaluated by MTS assay and apoptotic cells were analyzed using flow cytometry. To verify the antitumor effect of US irradiation on PC in vivo, we conducted animal experiments using mice. TRAMP-C2-bearing mice were irradiated with US with PRF of 10 and 100 Hz. Three weeks after the start of US irradiation, anti-PD-1 antibody was administered to the mice. Finally, mice were sacrificed and tumors were collected. Immunohistochemical (IHC) analyses were assessed for cleaved caspase-3 and CD3 in tumor cell extracts. Results: Cell proliferation assays showed that 1 and 10 Hz US significantly inhibited cell survival (p < 0.0001). In addition, US irradiation induced apoptosis at 1, 10, and 100 Hz (p = 0.0129, p = 0.0150, and p = 0.0017, respectively). In animal experiments, a significant tumor growth inhibitory effect was observed at 10 and 100 Hz, and 100 Hz + ICIs (p < 0.05, respectively). Hematoxylin–eosin (H–E) staining showed a significant increase in the necrotic area of the tumor at 100 Hz and 100 Hz + ICIs (p < 0.05, respectively). In addition, under IHC staining the expression level of cleaved caspase-3 and the number of CD3-positive cells increased at 100 Hz (p < 0.05, respectively). Conclusion: US irradiation induced apoptosis in cells and reduced cell viability. In vivo tumor growth was suppressed by combined treatment with US irradiation and ICIs. Further research on immune system activation will lead to less invasive and more efficient treatments for PC.
format Online
Article
Text
id pubmed-9104877
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91048772022-05-14 Combined Treatment with Ultrasound and Immune Checkpoint Inhibitors for Prostate Cancer Hayashi, Fuuka Shigemura, Katsumi Maeda, Koki Hiraoka, Aya Maeshige, Noriaki Ooya, Tooru Sung, Shian-Ying Yang, Yong-Ming Fujisawa, Masato J Clin Med Article Background: Ultrasound (US) is mostly used for diagnostic purpose but could be used for cancer treatments with a US intensity or frequency fitted to such a purpose. Prostate cancer (PC) has the highest prevalence in the urological field, but indications for immune checkpoint inhibitors (ICIs) for PC are limited to very few cases. In this study, we compared the antitumor effect of US irradiation alone with the combined use of US and ICIs in vitro and in vivo. Methods: PC cell line TRAMP-C2 cells were used in our experiments. TRAMP-C2 cells were irradiated with US with pulse repeated frequencies (PRF) of 1, 10, and 100 Hz. Cell proliferation was evaluated by MTS assay and apoptotic cells were analyzed using flow cytometry. To verify the antitumor effect of US irradiation on PC in vivo, we conducted animal experiments using mice. TRAMP-C2-bearing mice were irradiated with US with PRF of 10 and 100 Hz. Three weeks after the start of US irradiation, anti-PD-1 antibody was administered to the mice. Finally, mice were sacrificed and tumors were collected. Immunohistochemical (IHC) analyses were assessed for cleaved caspase-3 and CD3 in tumor cell extracts. Results: Cell proliferation assays showed that 1 and 10 Hz US significantly inhibited cell survival (p < 0.0001). In addition, US irradiation induced apoptosis at 1, 10, and 100 Hz (p = 0.0129, p = 0.0150, and p = 0.0017, respectively). In animal experiments, a significant tumor growth inhibitory effect was observed at 10 and 100 Hz, and 100 Hz + ICIs (p < 0.05, respectively). Hematoxylin–eosin (H–E) staining showed a significant increase in the necrotic area of the tumor at 100 Hz and 100 Hz + ICIs (p < 0.05, respectively). In addition, under IHC staining the expression level of cleaved caspase-3 and the number of CD3-positive cells increased at 100 Hz (p < 0.05, respectively). Conclusion: US irradiation induced apoptosis in cells and reduced cell viability. In vivo tumor growth was suppressed by combined treatment with US irradiation and ICIs. Further research on immune system activation will lead to less invasive and more efficient treatments for PC. MDPI 2022-04-27 /pmc/articles/PMC9104877/ /pubmed/35566574 http://dx.doi.org/10.3390/jcm11092448 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Hayashi, Fuuka
Shigemura, Katsumi
Maeda, Koki
Hiraoka, Aya
Maeshige, Noriaki
Ooya, Tooru
Sung, Shian-Ying
Yang, Yong-Ming
Fujisawa, Masato
Combined Treatment with Ultrasound and Immune Checkpoint Inhibitors for Prostate Cancer
title Combined Treatment with Ultrasound and Immune Checkpoint Inhibitors for Prostate Cancer
title_full Combined Treatment with Ultrasound and Immune Checkpoint Inhibitors for Prostate Cancer
title_fullStr Combined Treatment with Ultrasound and Immune Checkpoint Inhibitors for Prostate Cancer
title_full_unstemmed Combined Treatment with Ultrasound and Immune Checkpoint Inhibitors for Prostate Cancer
title_short Combined Treatment with Ultrasound and Immune Checkpoint Inhibitors for Prostate Cancer
title_sort combined treatment with ultrasound and immune checkpoint inhibitors for prostate cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9104877/
https://www.ncbi.nlm.nih.gov/pubmed/35566574
http://dx.doi.org/10.3390/jcm11092448
work_keys_str_mv AT hayashifuuka combinedtreatmentwithultrasoundandimmunecheckpointinhibitorsforprostatecancer
AT shigemurakatsumi combinedtreatmentwithultrasoundandimmunecheckpointinhibitorsforprostatecancer
AT maedakoki combinedtreatmentwithultrasoundandimmunecheckpointinhibitorsforprostatecancer
AT hiraokaaya combinedtreatmentwithultrasoundandimmunecheckpointinhibitorsforprostatecancer
AT maeshigenoriaki combinedtreatmentwithultrasoundandimmunecheckpointinhibitorsforprostatecancer
AT ooyatooru combinedtreatmentwithultrasoundandimmunecheckpointinhibitorsforprostatecancer
AT sungshianying combinedtreatmentwithultrasoundandimmunecheckpointinhibitorsforprostatecancer
AT yangyongming combinedtreatmentwithultrasoundandimmunecheckpointinhibitorsforprostatecancer
AT fujisawamasato combinedtreatmentwithultrasoundandimmunecheckpointinhibitorsforprostatecancer